<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-145891" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Laboratory Evaluation of Immune Hemolytic Anemias</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathi</surname>
            <given-names>Alok K.</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname> Chuda</surname>
            <given-names>Ravindra</given-names>
          </name>
          <aff>University of Kansas School of Medicine, Kansas City, KS</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alok Tripathi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ravindra Chuda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>9</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-145891.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Immune hemolytic anemias are disorders characterized by the immune system targeting and destroying red blood cells (RBCs). These conditions are classified based on factors such as the type of antibody involved, the temperature&#x000a0;when hemolysis occurs, and whether the hemolysis is extravascular or intravascular. The immune-mediated destruction of&#x000a0;RBCs can occur through several mechanisms, including the production of autoantibodies against self-antigens on RBCs, alloantibodies directed against foreign antigens on transfused RBCs, or drug-induced antibodies that bind to RBCs or trigger complement activation.</p>
        <p>Immune hemolytic anemias are categorized into autoimmune, alloimmune, and drug-induced mechanisms, each with unique etiologies and pathophysiological processes. Autoimmune hemolytic anemias (AIHAs) include warm AIHA, cold agglutinin disease, and mixed-type AIHA. The most common form of AIHA is warm AIHA, which is mediated by immunoglobulin G (IgG) antibodies and is often associated with hematologic, autoimmune, and infectious conditions. Cold agglutinin disease involves IgM antibodies that react at cold temperatures, and paroxysmal cold hemoglobinuria features an IgG autoantibody causing hemolysis upon rewarming. Alloimmune hemolytic anemia occurs when alloantibodies attack foreign RBC antigens, typically following blood transfusions or during hemolytic disease of the newborn. Drug-induced immune hemolytic anemia (DIIHA) occurs when drug-induced antibodies bind to and destroy RBCs.</p>
        <p>Laboratory evaluation is crucial for diagnosing and managing immune hemolytic anemias. Diagnostic tests include complete blood count (CBC), haptoglobin, lactate dehydrogenase (LDH), reticulocyte count, bilirubin levels, and direct antiglobulin test (DAT) or indirect antiglobulin test. Peripheral blood smears, tests for cold agglutinins, Donath-Landsteiner antibodies, and other specialized tests are essential for accurate diagnosis.</p>
      </sec>
      <sec id="article-145891.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>
<bold>Etiology</bold>
</p>
        <p>Immune hemolytic anemia encompasses a spectrum of disorders characterized by the destruction of RBCs mediated by the immune system. The etiology can be categorized into autoimmune, alloimmune, and drug-induced mechanisms.</p>
        <p><bold>Autoimmune hemolytic anemia:&#x000a0;</bold>AIHA occurs when the immune system produces autoantibodies that target self-antigens on RBCs, leading to their destruction. AIHA can be classified into warm AIHA, cold agglutinin disease, and mixed-type AIHA.</p>
        <list list-type="bullet">
          <list-item>
            <p>Warm AIHA is the most common subtype, characterized by autoantibodies of the IgG class that react optimally at body temperature. However, IgA and warm-acting IgM have also been reported.</p>
          </list-item>
          <list-item>
            <p>Cold agglutinin disease involves cold-reactive IgM antibodies that agglutinate RBCs at low temperatures, causing intravascular hemolysis upon rewarming.</p>
          </list-item>
          <list-item>
            <p>Mixed-type AIHA exhibits features of both warm and cold antibody-mediated hemolysis.</p>
          </list-item>
        </list>
        <p>Paroxysmal cold hemoglobinuria is an acquired hemolytic anemia characterized by an IgG autoantibody that activates complement at cold temperatures, leading to intravascular hemolysis upon rewarming, accompanied by hemoglobinuria (see <bold>Table 1.</bold> Common Secondary Conditions Associated With Various Autoimmune Hemolytic Anemias).<xref ref-type="bibr" rid="article-145891.r1">[1]</xref></p>
        <p><bold>Alloimmune hemolytic anemia:&#x000a0;</bold>Alloimmune hemolytic anemia arises from the production of alloantibodies against foreign RBC antigens, often in the context of blood transfusions or hemolytic disease of the newborn. In hemolytic disease of the newborn, maternal antibodies directed against fetal RBC antigens lead to hemolysis in the fetus or newborn.&#x000a0;&#x000a0;</p>
        <p><bold>Drug-induced immune hemolytic anemia:&#x000a0;</bold>This anemia occurs when drugs or their metabolites produce antibodies that bind to and destroy RBCs. Frequently implicated drugs include penicillins, cephalosporins, and nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, certain anticancer drugs, such as platinum compounds and immune checkpoint inhibitors, are common triggers.<xref ref-type="bibr" rid="article-145891.r2">[2]</xref><xref ref-type="bibr" rid="article-145891.r3">[3]</xref><xref ref-type="bibr" rid="article-145891.r4">[4]</xref><xref ref-type="bibr" rid="article-145891.r5">[5]</xref><xref ref-type="bibr" rid="article-145891.r6">[6]</xref></p>
        <table-wrap id="article-145891.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.&#x000a0;Common Secondary Conditions Associated With Various Autoimmune Hemolytic Anemias</title>
          </caption>
          <table style="height: 100px; width: 800px;" border="1" cellspacing="2" cellpadding="2">
            <tbody>
              <tr style="height: 44.1875px;">
                <td style="width: 226.762px; height: 44.1875px;" rowspan="1" colspan="1">
<bold>Categories</bold>
</td>
                <td style="width: 718.238px; height: 44.1875px;" rowspan="1" colspan="1">
<bold>Etiologies</bold>
</td>
              </tr>
              <tr style="height: 298px;">
                <td style="width: 226.762px; height: 298px;" rowspan="1" colspan="1">Warm AIHA</td>
                <td style="width: 718.238px; height: 298px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Hematological disorders and lymphoproliferative diseases (eg, chronic lymphocytic leukemia, Hodgkin and non-Hodgkin lymphoma, autoimmune lymphoproliferative syndrome, and monoclonal gammopathies such as multiple myeloma, monoclonal gammopathy of undetermined significance, and Waldenstr&#x000f6;m macroglobulinemia)</p></list-item></list>
<list list-type="bullet"><list-item><p>Solid malignancy (eg, thymoma and ovarian or prostate carcinoma)</p></list-item></list>
<list list-type="bullet"><list-item><p>Autoimmune diseases (eg, systemic lupus erythematosus, Sj&#x000f6;gren syndrome,&#x000a0;systemic&#x000a0;sclerosis, rheumatoid arthritis, ulcerative colitis, and primary biliary cirrhosis)</p></list-item></list>
<list list-type="bullet"><list-item><p>Viral infections (eg, hepatitis C, HIV, varicella, cytomegalovirus, Epstein-Barr virus, SARS-CoV-2, and hepatitis E)</p></list-item></list>
<list list-type="bullet"><list-item><p>Bacterial infections (eg, tuberculosis and pneumococcal infections)</p></list-item></list>
<list list-type="bullet"><list-item><p>Leishmania and Babesia</p></list-item></list>
<list list-type="bullet"><list-item><p>Bone marrow or solid-organ transplantation</p></list-item></list>
<list list-type="bullet"><list-item><p>Primary immune deficiency syndromes (eg, common variable immunodeficiency and autoimmune lymphoproliferative syndrome).</p></list-item></list>
<list list-type="bullet"><list-item><p>Sarcoidosis</p></list-item></list>
<list list-type="bullet"><list-item><p>Pregnancy&#x000a0;<xref ref-type="bibr" rid="article-145891.r7">[7]</xref><xref ref-type="bibr" rid="article-145891.r8">[8]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 109px;">
                <td style="width: 226.762px; height: 109px;" rowspan="1" colspan="1">Cold agglutinin disease</td>
                <td style="width: 718.238px; height: 109px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lymphoproliferative diseases (eg, Waldenstr&#x000f6;m macroglobulinemia and non-Hodgkin lymphoma)</p></list-item></list>
<list list-type="bullet"><list-item><p>Infections (parvovirus B19, <italic toggle="yes">Mycoplasma sp</italic>, adenovirus, influenza virus,&#x000a0;varicella&#x000a0;and syphilis)</p></list-item></list>
<list list-type="bullet"><list-item><p>Autoimmune diseases</p></list-item></list>
<list list-type="bullet"><list-item><p>Post-allogeneic&#x000a0;hematopoietic stem cell transplantation</p></list-item></list>
</td>
              </tr>
              <tr style="height: 109px;">
                <td style="width: 226.762px; height: 109px;" rowspan="1" colspan="1">Paroxysmal cold hemoglobinuria</td>
                <td style="width: 718.238px; height: 109px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Bacterial infections (caused by&#x000a0;<italic toggle="yes">Mycoplasma pneumoniae</italic>,&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>,&#x000a0;<italic toggle="yes">Escherichia coli,</italic>&#x000a0;and <italic toggle="yes">Treponema pallidum</italic> [syphilis])</p></list-item></list>
<list list-type="bullet"><list-item><p>Viral infections (eg, adenovirus, influenza A virus, varicella, mumps, measles, and COVID-19)</p></list-item></list>
<list list-type="bullet"><list-item><p>Visceral leishmaniasis</p></list-item></list>
<list list-type="bullet"><list-item><p>Myeloproliferative disorders</p></list-item></list>
</td>
              </tr>
              <tr style="height: 84px;">
                <td style="width: 226.762px; height: 84px;" rowspan="1" colspan="1">Mixed AIHA</td>
                <td style="width: 718.238px; height: 84px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lymphoma</p></list-item></list>
<list list-type="bullet"><list-item><p>Systemic lupus erythematosus&#x000a0;</p></list-item></list>
<list list-type="bullet"><list-item><p>Miscellaneous infections</p></list-item></list>
</td>
              </tr>
              <tr style="height: 158px;">
                <td style="width: 226.762px; height: 158px;" rowspan="1" colspan="1">DIIHA</td>
                <td style="width: 718.238px; height: 158px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Antibiotics (such as cephalosporins, &#x003b2;-lactamase inhibitors, and cotrimoxazole)</p></list-item></list>
<list list-type="bullet"><list-item><p>Antiviral drugs: Highly active antiretroviral therapy</p></list-item></list>
<list list-type="bullet"><list-item><p>Anti-PD-1 monoclonal antibodies (nivolumab, pembrolizumab, ipilimumab and atezolizumab)</p></list-item></list>
<list list-type="bullet"><list-item><p>Chemotherapy (fludarabine, carboplatin, and oxaliplatin)</p></list-item></list>
<list list-type="bullet"><list-item><p>NSAIDs (diclofenac)</p></list-item></list>
<list list-type="bullet"><list-item><p>Others: Methyldopa</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>
<bold>Epidemiology</bold>
</bold>
</p>
        <p>The epidemiology of AIHA varies depending on the underlying etiology. Warm AIHA is the most prevalent subtype, with a bimodal age distribution peaking in young adulthood and later in life.<xref ref-type="bibr" rid="article-145891.r9">[9]</xref>&#x000a0;Warm AIHA shows a&#x000a0;slight predominance in women.<xref ref-type="bibr" rid="article-145891.r3">[3]</xref>&#x000a0;Cold agglutinin disease predominantly affects older adults in their late 60s and early 70s and is often secondary to underlying conditions such as infections or lymphoproliferative disorders. Cold agglutinin disease is slightly more prevalent in women and accounts for 15% to 30% of all hemolytic anemia cases.&#x000a0;</p>
        <p>Paroxysmal cold hemoglobinuria accounts for less than 1% of all hemolytic anemias. This condition is often considered&#x000a0;a pediatric disease, with a median age of 5, and occurs in 57% of cases,&#x000a0;especially&#x000a0;in patients aged 10 or younger.<xref ref-type="bibr" rid="article-145891.r10">[10]</xref>&#x000a0;Mixed AIHA accounts for less than 10% of all hemolytic anemia cases. Alloimmune hemolytic anemia occurs in approximately 1 to 3 per 1000 pregnancies and is more common in individuals with a history of multiple transfusions. DIIHA is relatively rare but can occur in patients exposed to offending drugs.<xref ref-type="bibr" rid="article-145891.r11">[11]</xref><xref ref-type="bibr" rid="article-145891.r12">[12]</xref><xref ref-type="bibr" rid="article-145891.r13">[13]</xref></p>
      </sec>
      <sec id="article-145891.s3" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The detailed pathophysiology of autoimmune hemolytic anemias is mentioned below, focusing on the primary target antigens and corresponding DAT biomarkers (see <bold>Table 2.</bold> Pathophysiology of Autoimmune Hemolytic Anemia).</p>
        <p>
<bold>Warm Autoimmune Hemolytic Anemia</bold>
</p>
        <p>Warm AIHA occurs when the body's immune system mistakenly attacks its own RBCs, destroying them. This type of anemia can occur spontaneously without any apparent cause, known as primary or idiopathic warm AIHA, or it can develop secondary to certain underlying conditions or medications that trigger the production of autoantibodies targeting RBCs. The autoantibodies involved in warm AIHA are predominantly of the IgG type, although IgA and warm-acting IgM antibodies have also been reported. Subtypes of IgG, such as IgG1 and IgG3, can activate the complement system and cause more severe hemolysis than other subtypes. These antibodies typically target common antigens found on the surface of RBCs, with the most frequently targeted antigens including those of the Rh complex and glycophorin antigens, which are heavily glycosylated proteins on the membrane.<xref ref-type="bibr" rid="article-145891.r2">[2]</xref><xref ref-type="bibr" rid="article-145891.r14">[14]</xref></p>
        <p>In warm AIHA, the primary site of hemolysis is extravascular, predominantly within lymphoid organs such as the spleen. This process is primarily mediated by the Fc fragment of IgG through antibody-dependent cellular cytotoxicity. Minimal hemolysis is attributed to complement coating in warm AIHA. This leads to the formation of small, round cells called microspherocytes, which are less malleable than normal RBCs and can become trapped in the spleen's sinusoids, prolonging their destruction. In severe cases, intravascular hemolysis may occur if the reticuloendothelial system is overwhelmed or if the complement membrane attack complex is deposited on the surface of RBCs.<xref ref-type="bibr" rid="article-145891.r3">[3]</xref></p>
        <p>Approximately 50% to 60% of warm AIHA cases are associated with underlying conditions, while the remaining cases are considered primary or idiopathic. Underlying conditions linked to secondary warm AIHA include various infections such as HIV, Epstein-Barr virus, hepatitis C, and, more recently, hepatitis E virus.<xref ref-type="bibr" rid="article-145891.r8">[8]</xref> Recently, COVID-19-associated warm&#x000a0;AIHA has been reported.<xref ref-type="bibr" rid="article-145891.r7">[7]</xref>&#x000a0;In addition, autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, or ulcerative colitis have been associated with warm AIHA.</p>
        <p>Lymphoproliferative disorders such as autoimmune lymphoproliferative syndrome, chronic lymphocytic leukemia (CLL), lymphoma, and monoclonal gammopathies are also associated with warm AIHA. Immunodeficiency states, especially inherited immunodeficiency, hematopoietic stem cell transplantation, solid organ transplantation, and hypogammaglobulinemia, can also precipitate warm AIHA.<xref ref-type="bibr" rid="article-145891.r15">[15]</xref>&#x000a0;Rarely, pregnancy and medications can trigger warm AIHA. Some unique causes include Babesiosis in asplenic patients and bites from the Brown recluse spider.<xref ref-type="bibr" rid="article-145891.r16">[16]</xref><xref ref-type="bibr" rid="article-145891.r17">[17]</xref></p>
        <p>
<bold>Cold Agglutinin Disease</bold>
</p>
        <p>Cold agglutinin disease is a rare autoimmune disorder characterized by autoantibodies, primarily of the IgM class, which exhibit reactivity against RBCs at temperatures below normal body temperature. Occasionally, IgG and IgA cold agglutinins have been reported, although IgA cold agglutinin does not cause cold agglutinin disease. The pathophysiology involves a complex interplay of immune mechanisms that culminate in the destruction of RBCs and subsequent anemia.<xref ref-type="bibr" rid="article-145891.r11">[11]</xref><xref ref-type="bibr" rid="article-145891.r18">[18]</xref><xref ref-type="bibr" rid="article-145891.r19">[19]</xref>&#x000a0;The underlying trigger for&#x000a0;cold agglutinin disease is the production of autoantibodies by the immune system.<xref ref-type="bibr" rid="article-145891.r20">[20]</xref> These autoantibodies typically target antigens, such as the I/i, GLOB, or P antigens, on the surface of RBCs.</p>
        <p>When the body is exposed to colder temperatures, particularly below 37 &#x000b0;C, these IgM autoantibodies bind to multiple RBCs, causing agglutination or clumping&#x02014;a process known as cold agglutination.<xref ref-type="bibr" rid="article-145891.r21">[21]</xref> This phenomenon is the hallmark of cold agglutinin disease and is responsible for many clinical manifestations. In cold agglutinin disease, IgM autoantibodies to RBCs bind to C1q, triggering activation of the complement cascade, a critical part of the innate immune response.<xref ref-type="bibr" rid="article-145891.r22">[22]</xref><xref ref-type="bibr" rid="article-145891.r23">[23]</xref>&#x000a0;Complement proteins, particularly C3b, are deposited on the surface of RBCs, which promotes their destruction. This complement activation enhances the opsonization of RBCs, making them more susceptible to phagocytosis by macrophages in the reticuloendothelial system, particularly in the liver by Kupffer cells, resulting in extravascular hemolysis.<xref ref-type="bibr" rid="article-145891.r24">[24]</xref>&#x000a0;Less commonly, in about 15% of cases, complement activation facilitates the formation of the membrane attack complex, leading to direct lysis of RBCs and subsequent hemoglobinuria, indicating intravascular hemolysis.<xref ref-type="bibr" rid="article-145891.r25">[25]</xref></p>
        <p>Cold agglutinin disease&#x000a0;is classified into primary (idiopathic) or secondary forms. Primary&#x000a0;cold agglutinin disease involves cold agglutinin-mediated destruction of RBCs and extravascular hemolysis without an underlying disorder. Patients with primary cold&#x000a0;agglutinin disease often have a low-grade clonal lymphoproliferative bone marrow disorder.<xref ref-type="bibr" rid="article-145891.r26">[26]</xref> Secondary cold agglutinin syndrome is typically precipitated by an underlying infection, autoimmune disease, or overt lymphoma. In older patients, cold agglutinin disease often presents as a primary disease with an underlying lymphoid malignancy such as B-cell or plasma cell disorders, aggressive non-Hodgkin lymphoma, or Waldenstr&#x000f6;m macroglobulinemia. Although solid tumors are rarely associated with primary cold agglutinin disease, this association is mostly uncommon.<xref ref-type="bibr" rid="article-145891.r27">[27]</xref>&#x000a0;Younger patients are more likely to have secondary&#x000a0;cold agglutinin disease precipitated from infection, commonly <italic toggle="yes">M pneumoniae</italic> or Epstein-Barr infection.<xref ref-type="bibr" rid="article-145891.r28">[28]</xref><xref ref-type="bibr" rid="article-145891.r29">[29]</xref>&#x000a0;Cases&#x000a0;have been reported of infections precipitating secondary cold agglutinin disease from HIV, influenza, rubella, varicella-zoster virus, and COVID-19.<xref ref-type="bibr" rid="article-145891.r30">[30]</xref><xref ref-type="bibr" rid="article-145891.r31">[31]</xref><xref ref-type="bibr" rid="article-145891.r32">[32]</xref><xref ref-type="bibr" rid="article-145891.r33">[33]</xref><xref ref-type="bibr" rid="article-145891.r34">[34]</xref></p>
        <p>
<bold>Paroxysmal Cold Hemoglobinuria</bold>
</p>
        <p>Paroxysmal cold hemoglobinuria is an acquired hemolytic anemia characterized by an IgG autoantibody that activates complement in cold temperatures, resulting in intravascular hemolysis upon rewarming, accompanied by hemoglobinuria. The exact mechanisms triggering autoantibody formation remain unclear, but this typically arises in the context of infections or autoimmune disorders, suggesting immune stimulation of autoantibody production. A proposed mechanism involves the generation of cross-reacting antibodies that target viral or bacterial antigens mimicking the P antigen on RBCs.</p>
        <p>The autoantibody in paroxysmal cold hemoglobinuria exhibits distinct characteristics, including specificity for the RBC GLOB antigen (formerly known as the P antigen)&#x02014;a polysaccharide antigen on the RBC surface.<xref ref-type="bibr" rid="article-145891.r35">[35]</xref> These antibodies are polyclonal, derived from multiple B-cell clones, and predominantly of the IgG class.<xref ref-type="bibr" rid="article-145891.r36">[36]</xref> Unlike cold agglutinins, which are typically IgM antibodies that induce RBC agglutination, these antibodies do not cause agglutination but instead bind to RBCs below normal body temperature. Upon rewarming, the antibodies dissociate, but complement proteins remain attached to RBCs, leading to complement-mediated intravascular hemolysis&#x02014;a hallmark of the anemia.</p>
        <p>Diagnosis of the anemia relies on detecting the presence of the Donath-Landsteiner antibody, which fixes complement in cold temperatures, contributing to intravascular hemolysis upon rewarming.<xref ref-type="bibr" rid="article-145891.r37">[37]</xref>&#x000a0;Historically, paroxysmal cold hemoglobinuria was described as a chronic condition in patients afflicted with tertiary or congenital syphilis. However, currently, the anemia is often precipitated by infections, especially upper respiratory tract infections, gastroenteritis, and <italic toggle="yes">M pneumoniae</italic>. Autoimmune disease and lymphoproliferative disorders have been associated, although to a lesser extent (&#x0003c;10%)&#x000a0;when compared to infectious etiology.<xref ref-type="bibr" rid="article-145891.r10">[10]</xref></p>
        <p>
<bold>Mixed Autoimmune Hemolytic Anemia</bold>
</p>
        <p>Mixed AIHA is a multifaceted hematological disorder characterized by the simultaneous presence of autoantibodies targeting different antigens on RBCs, resulting in hemolysis and anemia.<xref ref-type="bibr" rid="article-145891.r23">[23]</xref> The immune pathology underlying mixed AIHA involves diverse mechanisms contributing to RBC destruction and associated clinical manifestations. Autoantibodies in mixed AIHA can target various RBC antigens, including Rh, Kell, Duffy, and others, reflecting the heterogeneous nature of the immune response in this condition.</p>
        <p>The etiology of autoantibody production in mixed AIHA is often associated with underlying conditions such as autoimmune diseases, infections, or malignancies, which trigger immune dysregulation and stimulate the production of autoantibodies against RBC antigens.<xref ref-type="bibr" rid="article-145891.r21">[21]</xref> This process may involve molecular mimicry, where antigens from infectious agents or tumor cells share structural similarities with RBC antigens, leading to the production of cross-reactive antibodies. Complement activation is a critical aspect of the immune pathology in mixed AIHA, as complement-fixing autoantibodies initiate the complement cascade, resulting in complement-mediated hemolysis.<xref ref-type="bibr" rid="article-145891.r22">[22]</xref> This phenomenon involves depositing complement proteins on RBCs, which leads to their destruction through opsonization and the formation of the membrane attack complex.</p>
        <p>
<bold>Drug-Induced Immune Hemolytic Anemia</bold>
</p>
        <p>Immune-mediated destruction of RBCs primarily involves antibody-mediated mechanisms, where various antigen-antibody interactions lead to opsonization and subsequent phagocytosis by reticuloendothelial macrophages in the spleen and/or liver, resulting in extravascular hemolysis. While the&#x000a0;DAT (or the direct Coombs test) is typically positive, occasionally, a drug metabolite rather than the parent drug itself may be responsible, complicating diagnosis. This anemia can be categorized by different mechanisms, including drug-dependent reactions and alteration of RBC surface antigens. In drug-dependent reactions, the drug binds to RBCs and becomes part of the antigen-antibody complex, remaining firmly bound to the membrane or causing immune complex formation. RBC surface antigens are altered when drugs modify normal membrane components, leading to immune hemolysis weeks to months after drug initiation.<xref ref-type="bibr" rid="article-145891.r38">[38]</xref><xref ref-type="bibr" rid="article-145891.r39">[39]</xref></p>
        <p>Oxidative stress from certain drugs can induce hemolysis, especially in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or hemoglobin (Hb) H disease.<xref ref-type="bibr" rid="article-145891.r40">[40]</xref> Oxidant injury forms oxidizing radicals, leading to hemolysis via oxygen radical damage to RBC membrane components and cellular proteins. Additionally, drug-induced hemolysis can result in methemoglobinemia and thrombotic microangiopathy, necessitating prompt recognition and management.<xref ref-type="bibr" rid="article-145891.r41">[41]</xref>&#x000a0;More than 130 drugs have been associated with DIIHA.<xref ref-type="bibr" rid="article-145891.r42">[42]</xref> Immune hemolytic anemia is frequently triggered by antibiotics, particularly cephalosporins and penicillins. Certain anti-cancer drugs, such as fludarabine, platinum compounds, and immune checkpoint inhibitors, are common culprits.<xref ref-type="bibr" rid="article-145891.r5">[5]</xref><xref ref-type="bibr" rid="article-145891.r6">[6]</xref><xref ref-type="bibr" rid="article-145891.r43">[43]</xref></p>
        <table-wrap id="article-145891.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Pathophysiology of Autoimmune Hemolytic Anemia</title>
          </caption>
          <table style="height: 400px; width: 700px;" border="1" cellspacing="2" cellpadding="2">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">
<bold>Category</bold>
</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">
<bold>Pathophysiology</bold>
</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">
<bold>Primary Target Antigens</bold>
</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">
<bold>DAT as biomarker</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Warm AIHA</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Extravascular hemolysis</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Band 3</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">IgG &#x000b1; C3d</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Cold agglutinin disease</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Intravascular hemolysis</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">I/i antigens</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">C3d only</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Mixed AIHA</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Intra- and extravascular hemolysis</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Band 3; I/i antigens</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">IgG + C3d</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Paroxysmal cold hemoglobinuria</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">Intravascular hemolysis</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">GLOB (formally P antigen)</td>
                <td style="width: 268.75px; height: 13px;" rowspan="1" colspan="1">C3d</td>
              </tr>
              <tr style="height: 13.5px;">
                <td style="width: 268.75px; height: 13.5px;" rowspan="1" colspan="1">DIIHA</td>
                <td style="width: 268.75px; height: 13.5px;" rowspan="1" colspan="1">Intra-and extravascular hemolysis</td>
                <td style="width: 268.75px; height: 13.5px;" rowspan="1" colspan="1">Unknown</td>
                <td style="width: 268.75px; height: 13.5px;" rowspan="1" colspan="1">&#x000a0;IgG and/or C3d</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Alloimmune Hemolytic Anemia&#x000a0;</bold>
</p>
        <p>Alloimmune hemolytic anemia occurs when the immune system produces antibodies against RBC antigens perceived as foreign. This immune response can lead to the destruction of RBCs, resulting in anemia.&#x000a0;Alloimmune hemolytic anemia can be triggered by several scenarios, most importantly incompatible blood transfusions and hemolytic disease of the fetus and newborn.&#x000a0;Acute hemolytic transfusion reactions are typically caused by ABO incompatibility, most often due to clerical or procedural errors. These reactions involve the rapid destruction of RBCs when the recipient's immune system attacks transfused cells because they express an antigen foreign to the recipient. In rare instances, hemolysis can occur when transfused plasma contains antibodies targeting the recipient's RBC antigens. However, this is generally less severe due to the immediate dilution of donor antibodies upon transfusion.</p>
        <p>The first step involves recipient antibodies attaching to antigens on transfused RBCs. This typically requires prior sensitization through previous exposure, such as a prior transfusion or pregnancy. Patients with blood groups O, A, and B continuously produce antibodies against the A and B antigens they lack, often due to exposure to similar antigens on intestinal microorganisms. These naturally occurring antibodies, particularly IgM, can quickly activate complement, leading to rapid intravascular hemolysis in cases of ABO incompatibility. In some cases, transfusion with blood products containing high titers of ABO alloantibodies can also trigger a reaction.</p>
        <p>In hemolytic disease of the fetus and newborn, maternal sensitization in an RhD-negative individual occurs due to previous exposure to the Rh antigen, either through transfusion with Rh-positive RBCs or pregnancy with an Rh-positive offspring. Consequently, Rh hemolytic disease of the newborn generally does not occur in the first pregnancy in the absence of a transfusion history. Immunologically, antibody secretion begins with IgM, which cannot cross the placental barrier. This is later followed by isotype switching, leading to the production of IgG antibodies. IgG antibodies can cross the placental barrier, and they do so during the second and subsequent pregnancies, attacking the fetal RBCs and causing hemolysis and associated complications such as hydrops fetalis and jaundice.</p>
        <p>Hemolytic transfusion reactions can involve both intravascular and extravascular RBC destruction. When an antigen-antibody complex forms, it may activate the classical complement pathway. Complete complement activation on the RBC surface results in the formation of the membrane attack complex and causes intravascular hemolysis. If complement activation halts at the level of C3b, RBCs coated with IgG and C3b are primarily destroyed by macrophages in the liver. Destruction of RBCs coated with C3b is less effective. RBCs coated only with IgG are removed from circulation in the spleen. These cells can also be destroyed by macrophages or through antibody-dependent cellular cytotoxicity involving large lymphocytes (K cells) releasing perforins. Both intravascular and extravascular hemolysis can occur in acute and delayed hemolytic transfusion reactions, although their relative contributions may vary.<xref ref-type="bibr" rid="article-145891.r13">[13]</xref><xref ref-type="bibr" rid="article-145891.r44">[44]</xref><xref ref-type="bibr" rid="article-145891.r45">[45]</xref></p>
      </sec>
      <sec id="article-145891.s4" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>Diagnostic tests for the laboratory evaluation of immune hemolytic anemias are mentioned below (see&#x000a0;<bold>Table 3.&#x000a0;</bold>Serological Diagnoses of Autoimmune Hemolytic Anemia).</p>
        <p>
<bold>Complete Blood Count</bold>
</p>
        <p>CBC provides essential parameters such as hemoglobin concentration, hematocrit (Hct), RBC count, and mean corpuscular volume (MCV). In hemolytic anemia, a decreased hemoglobin and hematocrit&#x000a0;occurs due to the loss of RBCs. Typically, hemoglobin in a patient with immune hemolytic anemia ranges from 7 to 10 g/dL, although hemoglobin less than 7 g/dL can be observed in up to 30% of patients. Common CBC findings associated with immune hemolytic anemia include reticulocytosis, normal or increased MCV, and an elevated reticulocyte percentage.<xref ref-type="bibr" rid="article-145891.r46">[46]</xref>&#x000a0;</p>
        <p>
<bold>Haptoglobin</bold>
</p>
        <p>Haptoglobin binds free hemoglobin released from RBCs and is consumed during hemolysis. A decreased haptoglobin level indicates hemolysis, typically being low or undetectable in hemolytic anemia. A haptoglobin level of less than 25 mg/dL has an 87% probability of predicting hemolytic disease.<xref ref-type="bibr" rid="article-145891.r47">[47]</xref></p>
        <p>
<bold>Lactate Dehydrogenase</bold>
</p>
        <p>LDH is released from damaged RBCs and other cells during hemolysis. Elevated LDH levels are indicative of hemolysis, with median LDH levels around 500 units/L (U/L), although variations up to 5000 U/L have been reported. LDH levels are significantly elevated in intravascular hemolysis compared to only mild elevation in extravascular hemolysis.<xref ref-type="bibr" rid="article-145891.r20">[20]</xref><xref ref-type="bibr" rid="article-145891.r48">[48]</xref></p>
        <p>
<bold>Reticulocyte Count</bold>
</p>
        <p>Reticulocytes are immature RBCs released from the bone marrow in response to anemia. An elevated reticulocyte count (&#x0003e;2.5%) suggests an appropriate bone marrow response to hemolysis. The absolute reticulocyte count is preferred, as it is unaffected by hemoglobin concentration. If the absolute reticulocyte count is unavailable, the reticulocyte percentage can be corrected for the hemoglobin. Reticulocytopenia can occur in AIHA, secondary to bone marrow infiltration by a lymphoproliferative disorder or to parvovirus B19 infection.<xref ref-type="bibr" rid="article-145891.r23">[23]</xref><xref ref-type="bibr" rid="article-145891.r46">[46]</xref></p>
        <p>
<bold>Bilirubin</bold>
</p>
        <p>Increased levels of unconjugated bilirubin result from the breakdown of hemoglobin in hemolytic anemia.&#x000a0;Indirect bilirubin is typically elevated in 2 to 3 mg/dL (35-51 &#x003bc;mol/L) in immune hemolytic anemia.<xref ref-type="bibr" rid="article-145891.r49">[49]</xref></p>
        <p>
<bold>Direct Antiglobulin Test or Direct Coombs Test</bold>
</p>
        <p>This test detects antibodies or complement proteins bound to the surface of patient RBCs, indicating immune-mediated destruction. A positive result confirms immune hemolysis.<xref ref-type="bibr" rid="article-145891.r50">[50]</xref> This laboratory procedure involves the identification of antibodies or complement proteins bound to the surface of RBCs, indicating an immune response. The test is performed by collecting a blood sample from the patient, separating the RBCs from the plasma or serum, and washing the RBCs to remove any unbound antibodies or complement proteins. The RBC suspension is incubated with an antihuman globulin reagent, which specifically binds to antibodies or complement proteins attached to the RBC surface.</p>
        <p>After incubation, the RBCs are rewashed to remove the unbound reagent, and the suspension is examined microscopically for signs of agglutination or antibody binding. A positive result, indicated by agglutination, suggests antibodies or complement proteins bound to the RBC surface, confirming the diagnosis of immune-mediated hemolysis.<xref ref-type="bibr" rid="article-145891.r40">[40]</xref>&#x000a0;The direct Coombs test may be performed in different variations, including tube and gel methods, but the basic principle remains the same. The severity of hemolysis is generally correlated with the strength of DAT positivity.</p>
        <p>In patients with hemolytic anemia lacking recent transfusions or cold agglutinin or Donath-Landsteiner antibodies, a positive DAT for IgG and/or C3d is typically indicative of warm AIHA. Cold agglutinin disease is mainly characterized by DAT positivity for C3d (usually negative or weakly positive for IgG), indicating the involvement of IgM antibodies. For clinical significance, cold agglutinin titers are typically more than 512; however, levels above 64 are considered positive. Mixed AIHA manifests as DAT positivity for both IgG and high-titer cold agglutinins. Additionally, atypical forms of AIHA may occur, presenting as DAT-negative cases driven by IgA or warm IgM antibodies.<xref ref-type="bibr" rid="article-145891.r15">[15]</xref>&#x000a0;</p>
        <p>Paroxysmal cold hemoglobinuria is characterized by DAT positivity for C3d but negative for IgG/IgM. When evaluating alternatives, a positive DAT can also result from other conditions, including passive deposition of antibodies or immune complexes in liver disease, chronic infections, malignancies, systemic lupus erythematosus, renal disorders, and certain drug therapies such as intravenous immunoglobulin (IVIG) or anti-thymocyte globulin.<xref ref-type="bibr" rid="article-145891.r23">[23]</xref></p>
        <p>
<bold>Indirect Antiglobulin Test or Indirect Coombs Test</bold>
</p>
        <p>The&#x000a0;indirect antiglobulin tests&#x000a0;assess antibodies in the patient's serum that may react with donor RBCs. This test is essential for identifying alloantibodies and ensuring compatibility for blood transfusions.<xref ref-type="bibr" rid="article-145891.r51">[51]</xref>&#x000a0;This test is crucial for ensuring the compatibility of donor blood with the recipient's serum to prevent adverse reactions during blood transfusions and minimize the risk of hemolytic disease in the newborn. The procedure involves collecting a blood sample from the patient, isolating the serum containing antibodies, and incubating it with donor RBCs of known antigenic characteristics.&#x000a0;</p>
        <p>After incubation, the RBC suspension is washed to remove unbound antibodies. An antihuman globulin reagent containing antibodies that bind to human immunoglobulins on the surface of RBCs is then added. Subsequent incubation allows the reagent to bind to any antibodies attached to the RBC surface. The RBC suspension is examined microscopically for agglutination or other signs of antibody binding, with agglutination indicating a positive result. This suggests that antibodies in the patient's serum react with the donor RBC antigens. This positive result confirms circulating antibodies targeting RBC antigens and supports the diagnosis of AIHA.</p>
        <p>Furthermore, the indirect Coombs test aids in determining the specificity of the antibodies, which helps in guiding management decisions, including selecting appropriate blood products for transfusion and assessing the need for immunosuppressive therapy. Additionally, serial indirect Coombs testing can track changes in antibody titers over time, providing valuable insights into treatment response and disease progression in patients with AIHA.</p>
        <p>
<bold>Peripheral Smear</bold>
</p>
        <p>Examination of the peripheral blood smear allows visual inspection of RBC morphology, revealing characteristic changes such as spherocytes, schistocytes, and reticulocytosis indicative of hemolysis.<xref ref-type="bibr" rid="article-145891.r40">[40]</xref> Spherocytes are commonly seen in warm AIHA and paroxysmal cold hemoglobinuria, whereas in cold agglutinin disease, spherocytes may be present but are not usually abundant. In DIIHA, the presence of bite cells, blister cells, or irregularly shaped RBCs (poikilocytosis) suggests oxidative hemolysis, while spherocytes or microspherocytes indicate immune hemolysis. Schistocytes, on the other hand, suggest a thrombotic microangiopathy such as disseminated intravascular coagulation.</p>
        <p>
<bold>Donath-Landsteiner Antibody</bold>
</p>
        <p>Donath-Landsteiner testing is reserved for&#x000a0;patients&#x000a0;with clinical signs of paroxysmal cold hemoglobinuria&#x000a0;and&#x000a0;a positive Coombs test for C3d. This assay identifies an antibody that adheres to RBCs in cold conditions, activates complement, and disassociates upon warming, a characteristic known as "biphasic hemolysin." However, this testing method can be time-consuming, resource-intensive, and prone to inaccuracies due to&#x000a0;the low sensitivity.<xref ref-type="bibr" rid="article-145891.r52">[52]</xref> Results may only show positivity for high-titer antibodies during a brief period around the hemolytic episode. Therefore, a negative outcome in a patient with a convincing clinical presentation cannot be considered evidence against diagnosing paroxysmal cold hemoglobinuria.</p>
        <p>
<bold>Osmotic Fragility Test</bold>
</p>
        <p>Osmotic fragility measures the ability of RBCs to withstand swelling and lysis in a hypotonic solution. Increased fragility is characteristic of certain types of hemolytic anemia, such as hereditary spherocytosis.</p>
        <p>
<bold>Autoimmune Serological Markers</bold>
</p>
        <p>Tests for autoimmune markers, such as antinuclear antibodies and rheumatoid factor, may assess underlying autoimmune conditions associated with immune hemolytic anemia.</p>
        <p>
<bold>Bone Marrow Aspiration or Biopsy</bold>
</p>
        <p>In some cases, especially primary cold agglutinin disease, a bone marrow sample may be obtained to evaluate for evidence of increased erythropoiesis, erythroid hyperplasia, or abnormal cell infiltration, which can provide diagnostic insights into the underlying cause of hemolysis.<xref ref-type="bibr" rid="article-145891.r4">[4]</xref></p>
        <p>
<bold>Additional Testing</bold>
</p>
        <p>Additional testing may include serum IgG and immunofixation if a cold autoantibody is suspected. Testing for HIV, hepatitis B, hepatitis C, and hepatitis E can help diagnose secondary causes of warm AIHA. If reticulocytopenia is present, testing for Parvovirus B19 IgM could be considered. Imaging studies may evaluate lymphoproliferative diseases. In cases of suspected DAT-negative AIHA, additional monospecific DAT for IgM, IgG, IgA, and C3d can be performed.<xref ref-type="bibr" rid="article-145891.r23">[23]</xref><xref ref-type="bibr" rid="article-145891.r44">[44]</xref></p>
        <table-wrap id="article-145891.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3. Serological Diagnoses of Autoimmune Hemolytic Anemia</title>
          </caption>
          <table style="height: 300px; width: 700px;" border="1" cellspacing="2" cellpadding="2">
            <tbody>
              <tr>
                <td style="width: 269px;" rowspan="1" colspan="1">
<bold>Categories</bold>
</td>
                <td style="width: 269px;" rowspan="1" colspan="1">
<bold>DAT</bold>
</td>
                <td style="width: 269px;" rowspan="1" colspan="1">
<bold>Eluate</bold>
</td>
                <td style="width: 269px;" rowspan="1" colspan="1">
<bold>Serum Antibody</bold>
</td>
              </tr>
              <tr>
                <td style="width: 269px;" rowspan="1" colspan="1">Warm AIHA</td>
                <td style="width: 269px;" rowspan="1" colspan="1">
<p>IgG + (67%)</p>
<p>IgG + C3d (20%)&#x000a0;</p>
<p>C3d only (13%)</p>
</td>
                <td style="width: 269px;" rowspan="1" colspan="1">Positive IgG</td>
                <td style="width: 269px;" rowspan="1" colspan="1">IgG panagglutinin</td>
              </tr>
              <tr>
                <td style="width: 269px;" rowspan="1" colspan="1">Cold agglutinin disease</td>
                <td style="width: 269px;" rowspan="1" colspan="1">C3d only</td>
                <td style="width: 269px;" rowspan="1" colspan="1">Negative</td>
                <td style="width: 269px;" rowspan="1" colspan="1">
<p>Primary cold&#x000a0;agglutinin disease: Monoclonal agglutinin IgM</p>
<p>Secondary cold&#x000a0;agglutinin disease: Polyclonal agglutinin IgM</p>
</td>
              </tr>
              <tr>
                <td style="width: 269px;" rowspan="1" colspan="1">Mixed AIHA</td>
                <td style="width: 269px;" rowspan="1" colspan="1">IgG + C3d</td>
                <td style="width: 269px;" rowspan="1" colspan="1">Positive IgG</td>
                <td style="width: 269px;" rowspan="1" colspan="1">IgG panagglutinin +&#x000a0;agglutinating IgM with low titer but high thermal amplitude (&#x02264;37 &#x000b0;C)</td>
              </tr>
              <tr>
                <td style="width: 269px;" rowspan="1" colspan="1">Paroxysmal cold hemoglobinuria</td>
                <td style="width: 269px;" rowspan="1" colspan="1">C3d only</td>
                <td style="width: 269px;" rowspan="1" colspan="1">Negative</td>
                <td style="width: 269px;" rowspan="1" colspan="1">Cold-reactive IgG biphasic hemolysin:&#x000a0;Diagnosis made using Donath-Landsteiner (D-L) test, usually anti-GLOB, which fails to react with&#x000a0;P antigen RBCs</td>
              </tr>
              <tr>
                <td style="width: 269px;" rowspan="1" colspan="1">DIIHA</td>
                <td style="width: 269px;" rowspan="1" colspan="1">IgG only</td>
                <td style="width: 269px;" rowspan="1" colspan="1">
<p>Positive IgG</p>
<p>Can be positive for C3d</p>
</td>
                <td style="width: 269px;" rowspan="1" colspan="1">Positive IgG&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-145891.s5" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Several factors can interfere with the laboratory evaluation of immune hemolytic anemia, affecting the accuracy of test results and diagnostic interpretation. Some of the key interfering factors are listed below.</p>
        <p>
<bold>Sample Collection and Handling</bold>
</p>
        <p>Improper blood sample collection or handling can lead to hemolysis, affecting test results. Collecting blood samples using appropriate techniques and anticoagulants prevents hemolysis during transportation and processing.<xref ref-type="bibr" rid="article-145891.r53">[53]</xref></p>
        <p>
<bold>Medications</bold>
</p>
        <p>Certain medications, such as corticosteroids, immunosuppressants, and blood transfusions, can interfere with serological tests for&#x000a0;immune hemolytic anemia by affecting antibody levels or altering RBC antigen expression. Thus, the patient's medication history and the timing of drug administration should be considered when interpreting their test results.</p>
        <p>
<bold>Autoantibodies</bold>
</p>
        <p>Autoantibodies, such as cold agglutinins or warm-reactive autoantibodies, can complicate the interpretation of serological tests for immune hemolytic anemia. These autoantibodies may bind to RBCs nonspecifically, leading to false-positive results or masking the detection of specific alloantibodies.<xref ref-type="bibr" rid="article-145891.r40">[40]</xref></p>
        <p>
<bold>Transfusion History</bold>
</p>
        <p>Previous blood transfusions can result in donor-derived antibodies in the recipient's serum, leading to false-positive results on serological tests. Therefore, it is important to consider the patient's transfusion history and perform compatibility testing when interpreting test results.<xref ref-type="bibr" rid="article-145891.r54">[54]</xref></p>
        <p>
<bold>Underlying Medical Conditions</bold>
</p>
        <p>Underlying medical conditions, such as infections, autoimmune diseases, or malignancies, can affect a patient's immune system and antibody production, thereby influencing serological test results for immune hemolytic anemia. Evaluating the patient's clinical history and considering possible confounding factors when interpreting test results is important.<xref ref-type="bibr" rid="article-145891.r48">[48]</xref></p>
        <p>
<bold>Sample Quality</bold>
</p>
        <p>The reliability of test results can be compromised by factors affecting sample quality, such as sample contamination, inadequate volume, or improper storage conditions. Ensuring proper sample collection, labeling, and storage is essential to minimize the risk of sample-related interference.<xref ref-type="bibr" rid="article-145891.r55">[55]</xref></p>
        <p>
<bold>Technical Variability</bold>
</p>
        <p>Inconsistencies in test results can arise from variability in laboratory techniques, equipment, and reagents. Standardizing laboratory procedures and implementing robust quality control measures are essential to minimize technical variability and ensure the reliability of test results.<xref ref-type="bibr" rid="article-145891.r56">[56]</xref></p>
      </sec>
      <sec id="article-145891.s6" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>The information below should be included in the laboratory report for hemolytic anemia.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient information: Name, age, sex, and relevant medical history.</p>
          </list-item>
          <list-item>
            <p>Laboratory results: Results of CBC, peripheral blood smear interpretation, reticulocyte count, haptoglobin, LDH, bilirubin, Coombs test, and osmotic fragility test.</p>
          </list-item>
          <list-item>
            <p>Interpretation:&#x000a0;Analysis of the results in the context of hemolytic anemia, including any findings&#x000a0;to pinpoint the underlying cause.</p>
          </list-item>
          <list-item>
            <p>Recommendations:&#x000a0;Further tests or consultations are recommended based on the findings, such as genetic testing for hereditary hemolytic disorders or additional imaging studies.</p>
          </list-item>
        </list>
        <p>Critical findings in the laboratory evaluation of hemolytic anemia are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe anemia:&#x000a0;Hemoglobin&#x000a0;levels below a critical threshold necessitate prompt intervention to avoid complications such as tissue hypoxia.</p>
          </list-item>
          <list-item>
            <p>High reticulocyte count: Indicates active bone marrow response to hemolysis, suggesting RBC destruction.</p>
          </list-item>
          <list-item>
            <p>Significantly elevated LDH: Suggests extensive hemolysis and tissue damage, requiring immediate investigation and management.</p>
          </list-item>
          <list-item>
            <p>Positive direct Coombs test: Indicates immune-mediated hemolysis, which may require specific treatment modalities such as immunosuppressive therapy.</p>
          </list-item>
          <list-item>
            <p>Characteristic morphological changes on peripheral blood smear: Presence of schistocytes, spherocytes, or other abnormal RBC morphologies indicative of specific hemolytic disorders.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145891.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Diagnosing the specific type of hemolytic anemia is crucial for tailoring effective management strategies and optimizing patient outcomes. Distinguishing between different etiologies, such as AIHA, alloimmune hemolytic anemia, and other forms of hemolysis, guides treatment decisions and interventions. Identifying whether the condition involves warm or cold antibody-mediated mechanisms in AIHA influences treatment selection. Warm AIHA, characterized by IgG-mediated hemolysis, typically responds well to initial treatment with glucocorticoids and rituximab, particularly in symptomatic patients.<xref ref-type="bibr" rid="article-145891.r3">[3]</xref>&#x000a0;Conversely, cold AIHA, involving IgM antibodies and complement activation, may necessitate different therapeutic approaches, such as avoidance of cold exposure and, in severe cases, plasmapheresis or immunosuppressive therapy.&#x000a0;</p>
        <p>In symptomatic patients with cold agglutinin disease, whether or not a low-grade bone marrow lymphoproliferative disorder is detected, first-line treatment typically involves immunosuppressive therapy with rituximab monotherapy or a rituximab-bendamustine combination.<xref ref-type="bibr" rid="article-145891.r57">[57]</xref>&#x000a0;Paroxysmal cold hemoglobinuria is managed similarly to cold AIHA to avoid cold exposure; however, the efficacy of glucocorticoids has not been established.<xref ref-type="bibr" rid="article-145891.r10">[10]</xref>&#x000a0;The cornerstone of treatment in patients with&#x000a0;DIIHA involves discontinuation of the offending medication. Symptomatic cases may benefit from glucocorticoid therapy.<xref ref-type="bibr" rid="article-145891.r58">[58]</xref><xref ref-type="bibr" rid="article-145891.r59">[59]</xref>&#x000a0;Severe and relapsing cases may require further therapies such as IVIG therapeutic plasma exchange and/or rituximab.&#x000a0;</p>
        <p>Diagnosing alloimmune hemolytic anemia, particularly in the context of hemolytic disease of the newborn or hemolytic transfusion reactions, informs immediate management strategies. Identifying maternal antibodies targeting fetal RBCs, typically anti-D antibodies, allows for timely interventions, including intrauterine transfusions or postnatal treatments to mitigate complications such as hydrops fetalis and neonatal jaundice.<xref ref-type="bibr" rid="article-145891.r60">[60]</xref> Similarly,&#x000a0;recognizing the presence of alloantibodies in hemolytic transfusion reactions prompts immediate cessation of transfusion and supportive care measures to prevent further hemolysis and life-threatening complications.</p>
      </sec>
      <sec id="article-145891.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Utilizing a multidisciplinary approach significantly enhances healthcare outcomes in managing immune hemolytic anemia by capitalizing on collaborative efforts tailored to this complex condition. Timely diagnosis and treatment are imperative due to the potential for rapid disease progression and life-threatening complications. Unlike other forms of anemia, immune hemolytic anemia involves the immune-mediated destruction of RBCs, leading to acute anemia and associated symptoms such as fatigue, weakness, shortness of breath, and pallor.</p>
        <p>Prompt diagnosis is essential to prevent severe complications, including hemolytic crises, acute kidney injury, cardiovascular instability, and death. The underlying autoimmune processes may also be associated with systemic manifestations or comorbidities that require timely identification and intervention. Given the urgency of prompt intervention, a multidisciplinary approach involving physicians, hematologists, immunologists, laboratory technicians, nursing staff, and pharmacists is crucial.</p>
        <p>In this collaborative framework,&#x000a0;the interprofessional healthcare team collaborates&#x000a0;with hematologists and immunologists to interpret laboratory findings related to immune hemolytic anemia, diagnose underlying autoimmune processes, and devise individualized treatment plans tailored to the specific subtype of immune hemolytic anemia. Hematologists and immunologists contribute their expertise in understanding the pathophysiology and guiding treatment decisions. Laboratory technicians play a crucial role by performing the direct Coombs test, which detects immune-mediated hemolysis by identifying antibodies bound to RBCs. Their meticulous work ensures accurate and timely results, providing essential information for diagnosis and treatment monitoring.</p>
        <p>Nursing staff are pivotal in patient advocacy, monitoring for signs of hemolysis, administering treatments, and educating patients and families about the disease process and lifestyle modifications. By harnessing the collective skills and expertise of the multidisciplinary healthcare team, prompt diagnosis and treatment&#x000a0;are&#x000a0;facilitated, thereby reducing the risk of complications associated with untreated immune hemolytic anemia. Effective coordination and communication among healthcare team members ensures comprehensive care delivery, ultimately improving healthcare outcomes and enhancing the quality of life for patients with immune hemolytic anemia.</p>
      </sec>
      <sec id="article-145891.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145891&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145891">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/145891/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=145891">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-145891.s10">
        <title>References</title>
        <ref id="article-145891.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>341</fpage>
            <page-range>341-352</page-range>
            <pub-id pub-id-type="pmid">35282954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reusser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Osterwalder</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Speck</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up.</article-title>
            <source>Acta Haematol</source>
            <year>1987</year>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-6</page-range>
            <pub-id pub-id-type="pmid">3107324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodsky</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Warm Autoimmune Hemolytic Anemia.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>15</day>
            <volume>381</volume>
            <issue>7</issue>
            <fpage>647</fpage>
            <page-range>647-654</page-range>
            <pub-id pub-id-type="pmid">31412178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michalak</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Olewicz-Gawlik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rupa-Matysek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolny-Rokicka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nowakowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia: current knowledge and perspectives.</article-title>
            <source>Immun Ageing</source>
            <year>2020</year>
            <month>Nov</month>
            <day>20</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <pub-id pub-id-type="pmid">33292368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Citores</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Castejon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Villarreal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosado</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garcia-Marco</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.</article-title>
            <source>Exp Hematol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-73</page-range>
            <pub-id pub-id-type="pmid">20026377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fattizzo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rampi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2022</year>
            <month>Apr</month>
            <day>30</day>
            <volume>15</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35631383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazarian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Quinquenel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bellal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siavellis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacquy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Re</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Merabet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mekinian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Delmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cymbalista</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune haemolytic anaemia associated with COVID-19 infection.</article-title>
            <source>Br J Haematol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>190</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-31</page-range>
            <pub-id pub-id-type="pmid">32374906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leaf</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Leaf</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drews</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia in a young man with acute hepatitis E infection.</article-title>
            <source>Am J Hematol</source>
            <year>2017</year>
            <month>May</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>E77</fpage>
            <page-range>E77-E79</page-range>
            <pub-id pub-id-type="pmid">28230259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Hemolytic Anemias.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Oct</month>
            <day>07</day>
            <volume>385</volume>
            <issue>15</issue>
            <fpage>1407</fpage>
            <page-range>1407-1419</page-range>
            <pub-id pub-id-type="pmid">34614331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobs</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Figueroa Villalba</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review.</article-title>
            <source>Blood Adv</source>
            <year>2023</year>
            <month>Jun</month>
            <day>13</day>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>2520</fpage>
            <page-range>2520-2527</page-range>
            <pub-id pub-id-type="pmid">36716137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cold agglutinin disease.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2016</year>
            <month>Dec</month>
            <day>02</day>
            <volume>2016</volume>
            <issue>1</issue>
            <fpage>226</fpage>
            <page-range>226-231</page-range>
            <pub-id pub-id-type="pmid">27913484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokol</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stamps</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1981</year>
            <month>Jun</month>
            <day>20</day>
            <volume>282</volume>
            <issue>6281</issue>
            <fpage>2023</fpage>
            <page-range>2023-7</page-range>
            <pub-id pub-id-type="pmid">6788179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myle</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Al-Khattabi</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects.</article-title>
            <source>Pediatric Health Med Ther</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>491</fpage>
            <page-range>491-498</page-range>
            <pub-id pub-id-type="pmid">34675752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fattizzo</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The Changing Landscape of Autoimmune Hemolytic Anemia.</article-title>
            <source>Front Immunol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>946</fpage>
            <pub-id pub-id-type="pmid">32655543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fattizzo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zaninoni</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives.</article-title>
            <source>J Blood Med</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>265</fpage>
            <page-range>265-278</page-range>
            <pub-id pub-id-type="pmid">31496855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woolley</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Achebe</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Dunford</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Villeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Marty</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Post-Babesiosis Warm Autoimmune Hemolytic Anemia.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Mar</month>
            <day>09</day>
            <volume>376</volume>
            <issue>10</issue>
            <fpage>939</fpage>
            <page-range>939-946</page-range>
            <pub-id pub-id-type="pmid">28273010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eichner</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Spider bite hemolytic anemia: positive Coombs' test, erythrophagocytosis, and leukoerythroblastic smear.</article-title>
            <source>Am J Clin Pathol</source>
            <year>1984</year>
            <month>May</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>683</fpage>
            <page-range>683-7</page-range>
            <pub-id pub-id-type="pmid">6720633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ulvestad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Langholm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beiske</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hjorth-Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghanima</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rb&#x000f8;</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Tj&#x000f8;nnfjord</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.</article-title>
            <source>Haematologica</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>91</volume>
            <issue>4</issue>
            <fpage>460</fpage>
            <page-range>460-6</page-range>
            <pub-id pub-id-type="pmid">16585012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000f6;mer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rother</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Roelcke</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Failure of IgA cold agglutinin to activate C.</article-title>
            <source>Immunobiology</source>
            <year>1980</year>
            <month>Apr</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-6</page-range>
            <pub-id pub-id-type="pmid">7203511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fattizzo</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia.</article-title>
            <source>Dis Markers</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>635670</fpage>
            <pub-id pub-id-type="pmid">26819490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sundic</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.</article-title>
            <source>Biomed Res Int</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>363278</fpage>
            <pub-id pub-id-type="pmid">25705656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>How I treat cold agglutinin disease.</article-title>
            <source>Blood</source>
            <year>2021</year>
            <month>Mar</month>
            <day>11</day>
            <volume>137</volume>
            <issue>10</issue>
            <fpage>1295</fpage>
            <page-range>1295-1303</page-range>
            <pub-id pub-id-type="pmid">33512410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>QA</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2018</year>
            <month>Nov</month>
            <day>30</day>
            <volume>2018</volume>
            <issue>1</issue>
            <fpage>382</fpage>
            <page-range>382-389</page-range>
            <pub-id pub-id-type="pmid">30504336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zilow</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kirschfink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roelcke</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Red cell destruction in cold agglutinin disease.</article-title>
            <source>Infusionsther Transfusionsmed</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>410</fpage>
            <page-range>410-5</page-range>
            <pub-id pub-id-type="pmid">7873920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swiecicki</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hegerova</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cold agglutinin disease.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Aug</month>
            <day>15</day>
            <volume>122</volume>
            <issue>7</issue>
            <fpage>1114</fpage>
            <page-range>1114-21</page-range>
            <pub-id pub-id-type="pmid">23757733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma&#x00142;ecka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tr&#x000f8;en</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tierens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x000d8;stlie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ma&#x00142;ecki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Randen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tj&#x000f8;nnfjord</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Delabie</surname>
                <given-names>JMA</given-names>
              </name>
            </person-group>
            <article-title>Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease.</article-title>
            <source>Br J Haematol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>183</volume>
            <issue>5</issue>
            <fpage>838</fpage>
            <page-range>838-842</page-range>
            <pub-id pub-id-type="pmid">29265349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wortman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosse</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Logue</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cold agglutinin autoimmune hemolytic anemia in nonhematologic malignancies.</article-title>
            <source>Am J Hematol</source>
            <year>1979</year>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-83</page-range>
            <pub-id pub-id-type="pmid">484548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DeCredico</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hillman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Apr</month>
            <day>03</day>
            <volume>319</volume>
            <issue>13</issue>
            <fpage>1377</fpage>
            <page-range>1377-1378</page-range>
            <pub-id pub-id-type="pmid">29614161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horwitz</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Moulds</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Henle</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Henle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Polesky</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Balfour</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cold agglutinins in infectious mononucleosis and heterophil-antibody-negative mononucleosis-like syndromes.</article-title>
            <source>Blood</source>
            <year>1977</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-202</page-range>
            <pub-id pub-id-type="pmid">194643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciaffoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luzzati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roata</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Turrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Antonello</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Aprili</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Presence and significance of cold agglutinins in patients with HIV infection.</article-title>
            <source>Haematologica</source>
            <year>1992</year>
            <season>May-Jun</season>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-6</page-range>
            <pub-id pub-id-type="pmid">1427429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoindre</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boll&#x000e9;e</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lesavre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cold agglutinin syndrome associated with a 2009 influenza A H1N1 infection.</article-title>
            <source>Am J Med</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>e1</fpage>
            <page-range>e1-2</page-range>
            <pub-id pub-id-type="pmid">20843499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Schabel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sugg</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Roelcke</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia caused by IgG lambda-monotypic cold agglutinins of anti-Pr specificity after rubella infection.</article-title>
            <source>Transfusion</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>488</fpage>
            <page-range>488-92</page-range>
            <pub-id pub-id-type="pmid">11316899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Cold agglutinin disease with erythrophagocytosis by neutrophils occurring during recovery phase of chickenpox.</article-title>
            <source>J Lab Physicians</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-7</page-range>
            <pub-id pub-id-type="pmid">24701117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zagorski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pawar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rahimian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19).</article-title>
            <source>Br J Haematol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>190</volume>
            <issue>4</issue>
            <fpage>e183</fpage>
            <page-range>e183-e184</page-range>
            <pub-id pub-id-type="pmid">32460350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Celano</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Falkowski</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The specificity of the antibody in paroxysmal cold hemoglobinuria (P.C.H.).</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>1965</year>
            <month>Jun</month>
            <day>30</day>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>456</fpage>
            <page-range>456-61</page-range>
            <pub-id pub-id-type="pmid">5214829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Djaldetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paroxysmal cold hemoglobinuria.</article-title>
            <source>CRC Crit Rev Clin Lab Sci</source>
            <year>1978</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-83</page-range>
            <pub-id pub-id-type="pmid">401365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ipe</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Donath-Landsteiner test.</article-title>
            <source>Immunohematology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-6</page-range>
            <pub-id pub-id-type="pmid">30908069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Fueger</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Gottschall</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.</article-title>
            <source>Transfusion</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>697</fpage>
            <page-range>697-702</page-range>
            <pub-id pub-id-type="pmid">17381629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garratty</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Immune hemolytic anemia associated with drug therapy.</article-title>
            <source>Blood Rev</source>
            <year>2010</year>
            <season>Jul-Sep</season>
            <volume>24</volume>
            <issue>4-5</issue>
            <fpage>143</fpage>
            <page-range>143-50</page-range>
            <pub-id pub-id-type="pmid">20650555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gehrs</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Friedberg</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia.</article-title>
            <source>Am J Hematol</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>258</fpage>
            <page-range>258-71</page-range>
            <pub-id pub-id-type="pmid">11921020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tj&#x000f8;nnfjord</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.</article-title>
            <source>Blood Rev</source>
            <year>2012</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>107</fpage>
            <page-range>107-15</page-range>
            <pub-id pub-id-type="pmid">22330255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salama</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced immune hemolytic anemia.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-9</page-range>
            <pub-id pub-id-type="pmid">19236219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garratty</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced immune hemolytic anemia.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2009</year>
            <fpage>73</fpage>
            <page-range>73-9</page-range>
            <pub-id pub-id-type="pmid">20008184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loriamini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cserti-Gazdewich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Branch</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.</article-title>
            <source>Int J Mol Sci</source>
            <year>2024</year>
            <month>Apr</month>
            <day>12</day>
            <volume>25</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">38673882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strobel</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hemolytic Transfusion Reactions.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2008</year>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>346</fpage>
            <page-range>346-353</page-range>
            <pub-id pub-id-type="pmid">21512623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liesveld</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases.</article-title>
            <source>Blood</source>
            <year>1987</year>
            <month>Mar</month>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>820</fpage>
            <page-range>820-6</page-range>
            <pub-id pub-id-type="pmid">3814817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galen</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Van Lente</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The predictive value of serum haptoglobin in hemolytic disease.</article-title>
            <source>JAMA</source>
            <year>1980</year>
            <month>May</month>
            <day>16</day>
            <volume>243</volume>
            <issue>19</issue>
            <fpage>1909</fpage>
            <page-range>1909-11</page-range>
            <pub-id pub-id-type="pmid">7365971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fattizzo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zaninoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Radice</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nichele</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Di Bona</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lunghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tassinari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alfinito</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leporace</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Niscola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carpenedo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boschetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Revelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Consonni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scaramucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Fabritiis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tagariello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gaidano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cortelezzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zanella</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Nov</month>
            <day>06</day>
            <volume>124</volume>
            <issue>19</issue>
            <fpage>2930</fpage>
            <page-range>2930-6</page-range>
            <pub-id pub-id-type="pmid">25232059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birgens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Frederiksen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hasselbalch</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mourits-Andersen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Plesner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>R&#x000f8;nnov-Jessen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Klausen</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;llkopf</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.</article-title>
            <source>Br J Haematol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>163</volume>
            <issue>3</issue>
            <fpage>393</fpage>
            <page-range>393-9</page-range>
            <pub-id pub-id-type="pmid">23981017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r50">
          <label>50</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Theis</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>Coombs Test</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">31613487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kokoris</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Kalantzis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moschandreou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Papaioannou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grouzi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Panagglutination on the indirect antiglobulin test... this is the challenge!</article-title>
            <source>Asian J Transfus Sci</source>
            <year>2022</year>
            <season>Jul-Dec</season>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-262</page-range>
            <pub-id pub-id-type="pmid">36687552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeller</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Al Habsi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cserti-Gazdewich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delage</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lebrun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heddle</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients.</article-title>
            <source>Transfusion</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-143</page-range>
            <pub-id pub-id-type="pmid">27807852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giavarina</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Blood venous sample collection: Recommendations overview and a checklist to improve quality.</article-title>
            <source>Clin Biochem</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>10-11</issue>
            <fpage>568</fpage>
            <page-range>568-573</page-range>
            <pub-id pub-id-type="pmid">28242283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>QA</given-names>
              </name>
              <name>
                <surname>Stamps</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Provan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>A</given-names>
              </name>
              <collab>British Society for Haematology</collab>
            </person-group>
            <article-title>The diagnosis and management of primary autoimmune haemolytic anaemia.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>176</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-411</page-range>
            <pub-id pub-id-type="pmid">28005293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petz</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Cold antibody autoimmune hemolytic anemias.</article-title>
            <source>Blood Rev</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-15</page-range>
            <pub-id pub-id-type="pmid">17904258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segel</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review.</article-title>
            <source>Blood Cells Mol Dis</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>152</fpage>
            <page-range>152-60</page-range>
            <pub-id pub-id-type="pmid">24411920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berentsen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>How I manage patients with cold agglutinin disease.</article-title>
            <source>Br J Haematol</source>
            <year>2018</year>
            <month>May</month>
            <volume>181</volume>
            <issue>3</issue>
            <fpage>320</fpage>
            <page-range>320-330</page-range>
            <pub-id pub-id-type="pmid">29363757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>QA</given-names>
              </name>
              <name>
                <surname>Stamps</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Provan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>A</given-names>
              </name>
              <collab>British Society for Haematology Guidelines</collab>
            </person-group>
            <article-title>Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>177</volume>
            <issue>2</issue>
            <fpage>208</fpage>
            <page-range>208-220</page-range>
            <pub-id pub-id-type="pmid">28369704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanios</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Doley</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Munker</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.</article-title>
            <source>Eur J Haematol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-162</page-range>
            <pub-id pub-id-type="pmid">30347480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145891.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urbaniak</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Greiss</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>RhD haemolytic disease of the fetus and the newborn.</article-title>
            <source>Blood Rev</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-61</page-range>
            <pub-id pub-id-type="pmid">10805260</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
